Vanessa Gonzalez

12.1k total citations · 2 hit papers
20 papers, 5.6k citations indexed

About

Vanessa Gonzalez is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Vanessa Gonzalez has authored 20 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Vanessa Gonzalez's work include CAR-T cell therapy research (16 papers), Virus-based gene therapy research (4 papers) and CRISPR and Genetic Engineering (3 papers). Vanessa Gonzalez is often cited by papers focused on CAR-T cell therapy research (16 papers), Virus-based gene therapy research (4 papers) and CRISPR and Genetic Engineering (3 papers). Vanessa Gonzalez collaborates with scholars based in United States, Belgium and Denmark. Vanessa Gonzalez's co-authors include Simon F. Lacey, Carl H. June, J. Joseph Melenhorst, Bruce L. Levine, Stephan A. Grupp, Anne Chew, Noelle V. Frey, Pamela A. Shaw, Angela Shen and Zhaohui Zheng and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Vanessa Gonzalez

18 papers receiving 5.5k citations

Hit Papers

Chimeric Antigen Receptor T Cells for Sustained Remission... 2014 2026 2018 2022 2014 2015 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    2014 3.9k citations Shannon L. Maude, Noelle V. Frey et al. New England Journal of Medicine profile →
  2. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
    2015 1.3k citations David Porter, Wei‐Ting Hwang et al. Science Translational Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Vanessa Gonzalez United States 8 5.0k 1.8k 1.5k 1.5k 1.4k 20 5.6k
Zhaohui Zheng United States 17 5.6k 1.1× 2.1k 1.2× 1.8k 1.2× 1.7k 1.1× 1.5k 1.1× 32 6.5k
Nirali N. Shah United States 34 6.0k 1.2× 2.0k 1.1× 1.8k 1.2× 1.8k 1.2× 1.6k 1.1× 219 7.4k
Marianna Sabatino United States 28 3.5k 0.7× 1.7k 1.0× 1.4k 0.9× 970 0.7× 896 0.6× 87 4.8k
Frederick L. Locke United States 34 5.2k 1.0× 1.4k 0.8× 1.4k 1.0× 1.2k 0.8× 1.2k 0.8× 307 6.0k
Marco Ruella United States 29 3.2k 0.6× 1.3k 0.7× 1.3k 0.9× 1.1k 0.7× 809 0.6× 124 4.0k
Bambi Grilley United States 21 3.7k 0.7× 1.5k 0.8× 1.2k 0.8× 1.5k 1.0× 920 0.7× 69 4.4k
Anne Chew United States 19 8.4k 1.7× 3.3k 1.8× 2.5k 1.7× 2.6k 1.8× 2.3k 1.6× 34 9.6k
Constance M. Yuan United States 31 4.2k 0.8× 1.7k 0.9× 1.5k 1.0× 1.2k 0.8× 996 0.7× 121 5.9k
Enli Liu United States 19 4.5k 0.9× 2.1k 1.2× 1.8k 1.2× 1.7k 1.1× 1.3k 0.9× 31 5.6k
Mohamad Hamieh United States 14 3.8k 0.8× 1.5k 0.8× 1.7k 1.2× 1.2k 0.8× 1.3k 0.9× 26 4.6k

Countries citing papers authored by Vanessa Gonzalez

Since Specialization
Citations

This map shows the geographic impact of Vanessa Gonzalez's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Vanessa Gonzalez with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Vanessa Gonzalez more than expected).

Fields of papers citing papers by Vanessa Gonzalez

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Vanessa Gonzalez. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Vanessa Gonzalez. The network helps show where Vanessa Gonzalez may publish in the future.

Co-authorship network of co-authors of Vanessa Gonzalez

This figure shows the co-authorship network connecting the top 25 collaborators of Vanessa Gonzalez. A scholar is included among the top collaborators of Vanessa Gonzalez based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Vanessa Gonzalez. Vanessa Gonzalez is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Knopp, Michael V., Vincent Jannin, Vanessa Gonzalez, & Anette Müllertz. (2025). Utilizing the dynamic gastrointestinal model (DGM) to evaluate the gastric integrity of Capsugel® Enprotect® capsules in fasted and fed states. European Journal of Pharmaceutics and Biopharmaceutics. 219. 114962–114962.
2.
Bagley, Stephen, Zev A. Binder, Joseph A. Fraietta, et al.. (2025). A phase 1 study of intracerebroventricular (ICV) delivery of bivalent chimeric antigen receptor (CAR) T-cells targeting EGFR and IL13Ra2 in patients with recurrent glioblastoma (rGBM).. Journal of Clinical Oncology. 43(16_suppl). 102–102. 2 indexed citations
3.
Jadlowsky, Julie K., Rachel Leskowitz, S.J. McKenna, et al.. (2024). Long-term stability of clinical-grade lentiviral vectors for cell therapy. Molecular Therapy — Methods & Clinical Development. 32(1). 101186–101186. 7 indexed citations
4.
Logun, Meghan, Stephen Bagley, Daniel Zhang, et al.. (2023). CTIM-40. EARLY RADIOGRAPHIC RESPONSE AND ENGRAFTMENT OF PHASE I FIRST-IN-HUMAN BICISTRONIC CAR T CELLS CORRELATE WITH REAL-TIME AUTOLOGOUS GBM ORGANOID CYTOLYSIS. Neuro-Oncology. 25(Supplement_5). v72–v72. 1 indexed citations
5.
6.
Prieto-Centurion, Valentin, Kristen E. Holm, Richard Casaburi, et al.. (2023). A Hybrid Effectiveness/Implementation Clinical Trial of Adherence to Long-Term Oxygen Therapy for Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society. 20(11). 1561–1570. 1 indexed citations
7.
8.
Xu, Jun, Mercy Gohil, Edward A. Stadtmauer, et al.. (2020). Characterization of autologous T cells engineered to express NY-ESO-1 TCR with multiplexed CRISPR/Cas9 editing (NYCE T Cells). Cytotherapy. 22(5). S35–S36. 2 indexed citations
9.
Wang, Meng, Adam D. Cohen, Alfred L. Garfall, et al.. (2019). Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. Blood. 134(Supplement_1). 1909–1909. 6 indexed citations
10.
Cohen, Adam D., J. Joseph Melenhorst, Alfred L. Garfall, et al.. (2018). Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). Blood. 132(Supplement 1). 1974–1974. 10 indexed citations
11.
Gamaldo, Charlene E., Luis F. Buenaver, Oleg Chernyshev, et al.. (2018). Evaluation of Clinical Tools to Screen and Assess for Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine. 14(7). 1239–1244. 30 indexed citations
12.
Li, Amanda M., George Hucks, Amanda M. DiNofia, et al.. (2018). Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood. 132(Supplement 1). 556–556. 121 indexed citations
13.
Garfall, Alfred L., J. Joseph Melenhorst, Simon F. Lacey, et al.. (2018). PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. Blood. 132(Supplement 1). 1973–1973. 18 indexed citations
14.
Marcucci, Katherine T., Julie K. Jadlowsky, Wei‐Ting Hwang, et al.. (2017). Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients. Molecular Therapy. 26(1). 269–279. 91 indexed citations
15.
Maude, Shannon L., George Hucks, Alix E. Seif, et al.. (2017). The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL).. Journal of Clinical Oncology. 35(15_suppl). 103–103. 79 indexed citations
16.
Lacey, Simon F., Pamela A. Shaw, David T. Teachey, et al.. (2016). Biomarker Profiling Differentiates Sepsis from Cytokine Release Syndrome in Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia (ALL). Blood. 128(22). 2812–2812. 3 indexed citations
17.
Teachey, David T., Simon F. Lacey, Pamela A. Shaw, et al.. (2015). Biomarkers Accurately Predict Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Acute Lymphoblastic Leukemia (ALL). Blood. 126(23). 1334–1334. 4 indexed citations
18.
Porter, David, Wei‐Ting Hwang, Noelle V. Frey, et al.. (2015). Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine. 7(303). 303ra139–303ra139. 1317 indexed citations breakdown →
19.
Porter, David L., Simon F. Lacey, Wei‐Ting Hwang, et al.. (2014). Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL. Blood. 124(21). 1983–1983. 6 indexed citations
20.
Maude, Shannon L., Noelle V. Frey, Pamela A. Shaw, et al.. (2014). Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. New England Journal of Medicine. 371(16). 1507–1517. 3933 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zhaohui Zheng Breakdown of academic impact, for papers by Nirali N. Shah Breakdown of academic impact, for papers by Marianna Sabatino Breakdown of academic impact, for papers by Frederick L. Locke Breakdown of academic impact, for papers by Marco Ruella Breakdown of academic impact, for papers by Bambi Grilley Breakdown of academic impact, for papers by Anne Chew Breakdown of academic impact, for papers by Constance M. Yuan Breakdown of academic impact, for papers by Enli Liu Breakdown of academic impact, for papers by Mohamad Hamieh
Rankless by CCL
2026